RAMM Pharma Corp. (RAMMF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
RAMM Pharma Corp. (RAMMF) trades at $0.055. RAMM Pharma Corp. focuses on cannabinoid-based pharmaceutical formulations, cosmetics, and nutraceutical products. The company operates internationally, developing and selling products like Epifractán and XALEX 10. Market cap: $15.2M, Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for RAMMF: RAMMF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RAMMF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
RAMMF: 2/3 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →RAMM Pharma Corp. (RAMMF) Healthcare & Pipeline Overview
RAMM Pharma Corp., based in Canada, researches, develops, and sells cannabinoid-based pharmaceutical formulations, cosmetics, and nutraceuticals internationally. Its product portfolio includes prescription pharmaceuticals like XALEX 10 for refractory epilepsy and cannabis-based products for pets, positioning it within the evolving cannabis-derived healthcare market.
What Is the Investment Thesis for RAMMF?
RAMM Pharma Corp. presents a speculative investment opportunity within the cannabinoid pharmaceutical sector. The company's focus on developing and marketing cannabinoid-based products, including prescription drugs like XALEX 10, could drive revenue growth if these products gain regulatory approval and market acceptance. However, the company's negative profit margin of -265.1% indicates significant challenges in achieving profitability. The company's small market capitalization of $15.2M and negative beta of -0.60 suggest high volatility and sensitivity to market movements. Successful commercialization of its product pipeline and effective cost management are critical for RAMM Pharma to achieve sustainable growth. Investors should carefully consider the risks associated with investing in a small-cap pharmaceutical company operating in a rapidly evolving and highly regulated market.
Based on FMP financials and quantitative analysis
RAMMF Key Highlights
Market capitalization of $15.2M, indicating a small-cap company with potential for high growth but also higher risk.
- Negative P/E ratio of -0.20, reflecting current losses and the need for improved profitability.
- Profit margin of -265.1%, highlighting significant challenges in achieving profitability and efficient operations.
- Gross margin of 11.1%, suggesting limited pricing power and high cost of goods sold.
- Beta of -0.60, indicating a negative correlation with the market, which may offer some downside protection during market downturns but also limit upside potential.
Who Are RAMMF's Competitors?
RAMMF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATHJF Antisense Therapeutics Limited | $0.01 | -76.00% | $19.6M | 57 |
| HMPSF The Hempshire Group, Inc. | $0.19 | +0.00% | $15.7M | 41 |
| MGCLF MGC Pharmaceuticals Limited | $0.27 | +2.88% | $12.1M | 46 |
| MNNDF Nurosene Health Inc. | $0.33 | -8.71% | $14.3M | 46 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RAMMF's Key Strengths?
Proprietary cannabinoid pharmaceutical formulations.
- Presence in both pharmaceutical and consumer markets.
- Focus on specialized treatments like refractory epilepsy.
What Are RAMMF's Weaknesses?
Negative profit margin and ongoing losses.
- Small market capitalization and limited financial resources.
- Dependence on regulatory approvals for key products.
What Could Drive RAMMF Stock Higher?
Potential regulatory approvals for XALEX 10 in key markets, which could drive revenue growth.
- Expansion of the product portfolio through research and development of new cannabinoid-based formulations.
- Strategic partnerships and collaborations with established pharmaceutical companies.
What Are the Key Risks for RAMMF?
Negative return on equity (-96.8%) — the business is not currently generating profit on shareholder capital.
- Intense competition in the cannabinoid market, which could limit market share and pricing power.
- Evolving and uncertain regulatory landscape, which could impact product development and commercialization.
- Negative profit margin and ongoing losses, which raise concerns about financial sustainability.
- Dependence on regulatory approvals for key products, which could delay or prevent commercialization.
What Are the Growth Opportunities for RAMMF?
- Expansion of Product Portfolio: RAMM Pharma can expand its product portfolio by investing in research and development to create new cannabinoid-based formulations targeting specific medical conditions. The global cannabinoid market is projected to reach $47.2 billion by 2027, offering a substantial market opportunity for innovative products. Timeline: Ongoing, with new product launches expected within the next 2-3 years.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with established pharmaceutical companies or research institutions can accelerate product development and market access. Collaborations can provide access to funding, expertise, and distribution networks. The pharmaceutical industry is increasingly relying on partnerships to drive innovation. Timeline: Ongoing, with potential partnerships to be established within the next 1-2 years.
- Geographic Expansion: Expanding into new geographic markets, particularly in Europe and Latin America, where cannabis regulations are evolving, can drive revenue growth. These regions offer significant untapped market potential for cannabinoid-based products. Timeline: Within the next 3-5 years, focusing on regions with favorable regulatory environments.
- Increased Investment in Marketing and Sales: Investing in targeted marketing and sales initiatives to increase awareness and adoption of its products among healthcare professionals and consumers. Effective marketing can drive demand and build brand recognition. The pharmaceutical industry spends billions annually on marketing and sales. Timeline: Ongoing, with increased marketing efforts planned for the next year.
- Focus on Regulatory Approvals: Securing regulatory approvals for its pharmaceutical products, such as XALEX 10, in key markets. Regulatory approvals can significantly enhance the credibility and market access of these products. The regulatory approval process can be lengthy and costly but is essential for commercial success. Timeline: Ongoing, with regulatory submissions and approvals expected within the next 2-3 years.
What Are RAMMF's Competitive Advantages?
- Proprietary cannabinoid formulations.
- Established presence in the Canadian market.
- Focus on specialized pharmaceutical products like XALEX 10.
What Does RAMMF Do?
RAMM Pharma Corp., originally incorporated in 1987 as MTC Growth Fund-I Inc., rebranded in October 2019 to reflect its focus on cannabinoid-based products. Headquartered in Toronto, Canada, the company engages in the research, development, production, and sale of a diverse range of products, including cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and medical supplies. A key product is Epifractán, a cannabinoid pharmaceutical drug. The company also offers XALEX 10, a prescription pharmaceutical formulation designed for the treatment of refractory epilepsy. Additionally, RAMM Pharma markets NettaLife, a cannabis-based product line tailored for pets. RAMM Pharma operates both in Canada and internationally, seeking to capitalize on the growing market for cannabis-derived health and wellness products and prescription medications.
What Products and Services Does RAMMF Offer?
- Researches and develops cannabinoid pharmaceutical formulations.
- Produces and sells pharmaceutical products.
- Offers cosmetic products.
- Provides nutraceutical products.
- Resells medical supplies.
- Develops cannabis-based products for pets.
How Does RAMMF Make Money?
- Develops and manufactures cannabinoid-based products.
- Sells products through prescription and over-the-counter channels.
- Generates revenue through product sales in Canada and internationally.
What Industry Does RAMMF Operate In?
RAMM Pharma Corp. operates within the rapidly evolving cannabinoid pharmaceutical industry. This sector is characterized by increasing research into the therapeutic potential of cannabinoids, evolving regulatory landscapes, and growing consumer acceptance of cannabis-based products. The market is competitive, with companies ranging from large pharmaceutical firms to smaller, specialized players. RAMM Pharma's focus on developing and marketing cannabinoid-based pharmaceuticals, cosmetics, and nutraceuticals positions it to capitalize on this growth, but it also faces challenges related to regulatory hurdles, competition, and market volatility. The global legal cannabis market is projected to reach USD 102.2 billion by 2030, growing at a CAGR of 25.5% from 2022 to 2030.
Who Are RAMMF's Key Customers?
- Patients requiring cannabinoid-based treatments.
- Consumers seeking cosmetic and nutraceutical products.
- Pet owners looking for cannabis-based products for their pets.
- Healthcare providers prescribing medications.
Key Financial Metrics
Return on equity for RAMM Pharma Corp. stands at -96.8%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -62.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.66 means current liabilities exceed short-term assets, a liquidity point worth watching.
RAMMF Valuation & Market Position
With a $15.2M market cap, RAMM Pharma Corp. sits in the micro-cap segment of the market.
Company Profile
RAMM Pharma Corp. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Jackie Peter Burnett. RAMMF has traded publicly since 2020.
RAMMF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary cannabinoid pharmaceutical formulations.
- Presence in both pharmaceutical and consumer markets.
- Focus on specialized treatments like refractory epilepsy.
- Upcoming: Potential regulatory approvals for XALEX 10 in key markets, which could drive revenue growth.
Bear Case
- Negative profit margin and ongoing losses.
- Small market capitalization and limited financial resources.
- Dependence on regulatory approvals for key products.
- Potential: Intense competition in the cannabinoid market, which could limit market share and pricing power.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
RAMMF Latest News
No recent news available for RAMMF.
RAMMF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RAMMF.
Price Targets
Wall Street price target analysis for RAMMF.
RAMMF MoonshotScore
What does this score mean?
The MoonshotScore rates RAMMF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Jackie Peter Burnett
CEO
Jackie Peter Burnett serves as the CEO of RAMM Pharma Corp. His background includes experience in the pharmaceutical and healthcare industries, with a focus on strategic leadership and business development. Burnett has held various leadership positions in companies focused on developing and commercializing innovative healthcare solutions. His expertise spans areas such as product development, regulatory affairs, and market access.
Track Record: Under Jackie Peter Burnett's leadership, RAMM Pharma Corp. has focused on expanding its product portfolio and pursuing regulatory approvals for key pharmaceutical products. Burnett has overseen the company's efforts to develop and commercialize cannabinoid-based treatments, including XALEX 10. His strategic decisions have aimed to position RAMM Pharma as a player in the cannabinoid pharmaceutical market.
RAMMF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that RAMM Pharma Corp. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Higher price volatility.
- Potential for fraud or manipulation.
- Increased risk of delisting or going out of business.
- Verify the company's financial statements and disclosures.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Understand the regulatory environment and potential risks.
- Monitor trading volume and price movements.
- Consult with a financial advisor before investing.
- Be aware of the potential for fraud or manipulation.
- Established presence in the cannabinoid pharmaceutical market.
- Focus on developing specialized pharmaceutical products.
- Management team with experience in the healthcare industry.
What Investors Ask About RAMM Pharma Corp. (RAMMF) — Healthcare
What does RAMM Pharma Corp. do?
RAMM Pharma Corp. is a Canadian-based company engaged in the research, development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and medical supplies. The company's key products include Epifractán, a cannabinoid pharmaceutical drug, XALEX 10, a prescription pharmaceutical formulation for the treatment of refractory epilepsy, and NettaLife, a cannabis-based product line for pets.
What are the main risks for RAMMF?
The main risks for RAMMF include intense competition in the cannabinoid market, evolving and uncertain regulatory landscape, negative profit margin and ongoing losses, and dependence on regulatory approvals for key products. The company's small market capitalization and limited financial resources also increase the risk of financial distress.
What are the key factors to evaluate for RAMMF?
Evaluate RAMMF on fundamentals, analyst consensus, and risk factors. RAMM Pharma Corp. presents a speculative investment opportunity within the cannabinoid pharmaceutical sector. Not financial advice.
How frequently does RAMMF data refresh on this page?
RAMMF's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven RAMMF's recent stock price performance?
RAMM Pharma Corp. (RAMMF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary cannabinoid pharmaceutical formulations. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RAMMF overvalued or undervalued right now?
RAMM Pharma Corp. (RAMMF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research RAMMF before investing?
Before investing in RAMM Pharma Corp. (RAMMF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding RAMMF to a portfolio?
Key strength of RAMM Pharma Corp. (RAMMF): Proprietary cannabinoid pharmaceutical formulations. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC analysis is based on general characteristics of the OTC market and may not be specific to RAMMF.